GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

It is important for vulnerable people and the elderly to stay up to date on vaccinations such as influenza (to protect ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

With acute respiratory infections or lung-related illnesses rising in India, experts emphasise the need for increased adult ...

ACAM2000® and VIGIV to be delivered in 2024 and 2025GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Inc. (NYSE: EBS) today announced it has secured approximately $400 million in orders in 2024 ...

However, the current rate of adult vaccination in India is minuscule due to which millions of individuals remain vulnerable ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

PHILADELPHIA, PA, USA I September 18, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

Voluntary vaccination among adults can significantly reduce the incidence of lung infections, leading to fewer hospital ...

Shingles is “one of the worst pains in medicine.” A vaccine is highly effective at preventing it, but many people don’t get ...

More Australians will be able to get a free vaccine for the painful condition shingles. Aussies ages 18 to 64 who are classed ...